1. Age < 18 years <br/ > <br/ >2. Severe COVID-19 pneumonia: Individuals who test positive for SARS-CoV-2 using a virologic test (i.e., a nucleic acid amplification test [NAAT] or an antigen test), who show evidence of lower respiratory disease during clinical assessment or imaging and who have SpO2 <90% on room air at sea level or respiratory frequency >30 breaths/min <br/ > <br/ >3. Patients already on statins for dyslipidemia or cardiovascular disorders <br/ > <br/ >4. Hypersensitivity to statins. <br/ > <br/ >5. Active liver disease or unexplained persistent elevations of serum transaminases exceeding 2.5 times <br/ > <br/ >6. Pregnancy and lactating mothers. <br/ > <br/ >7. Concomitant treatment with the immunosuppressant cyclosporine or hepatitis C antivirals glecaprevir/pibrentasvir/tipranavir/ritonavir. <br/ >

1. Age < 18 years <br/ > <br/ >2. Severe COVID-19 pneumonia: Individuals who test positive for SARS-CoV-2 using a virologic test (i.e., a nucleic acid amplification test [NAAT] or an antigen test), who show evidence of lower respiratory disease during clinical assessment or imaging and who have SpO2 <90% on room air at sea level or respiratory frequency >30 breaths/min <br/ > <br/ >3. Patients already on statins for dyslipidemia or cardiovascular disorders <br/ > <br/ >4. Hypersensitivity to statins. <br/ > <br/ >5. Active liver disease or unexplained persistent elevations of serum transaminases exceeding 2.5 times <br/ > <br/ >6. Pregnancy and lactating mothers. <br/ > <br/ >7. Concomitant treatment with the immunosuppressant cyclosporine or hepatitis C antivirals glecaprevir/pibrentasvir/tipranavir/ritonavir. <br/ >

N/A

N/A

1. Age < 18 years <br/ > <br/ >2. Severe COVID-19 pneumonia: Individuals who test positive for SARS-CoV-2 using a virologic test (i.e., a nucleic acid amplification test [NAAT] or an antigen test), who show evidence of lower respiratory disease during clinical assessment or imaging and who have SpO2 <90% on room air at sea level or respiratory frequency >30 breaths/min <br/ > <br/ >3. Patients already on statins for dyslipidemia or cardiovascular disorders <br/ > <br/ >4. Hypersensitivity to statins. <br/ > <br/ >5. Active liver disease or unexplained persistent elevations of serum transaminases exceeding 2.5 times <br/ > <br/ >6. Pregnancy and lactating mothers. <br/ > <br/ >7. Concomitant treatment with the immunosuppressant cyclosporine or hepatitis C antivirals glecaprevir/pibrentasvir/tipranavir/ritonavir. <br/ >

1. Age < 18 years <br/ > <br/ >2. Severe COVID-19 pneumonia: Individuals who test positive for SARS-CoV-2 using a virologic test (i.e., a nucleic acid amplification test [NAAT] or an antigen test), who show evidence of lower respiratory disease during clinical assessment or imaging and who have SpO2 <90% on room air at sea level or respiratory frequency >30 breaths/min <br/ > <br/ >3. Patients already on statins for dyslipidemia or cardiovascular disorders <br/ > <br/ >4. Hypersensitivity to statins. <br/ > <br/ >5. Active liver disease or unexplained persistent elevations of serum transaminases exceeding 2.5 times <br/ > <br/ >6. Pregnancy and lactating mothers. <br/ > <br/ >7. Concomitant treatment with the immunosuppressant cyclosporine or hepatitis C antivirals glecaprevir/pibrentasvir/tipranavir/ritonavir. <br/ >